Document is current
Any future updates will be listed below
-
Authors
Tornero, C. https://orcid.org/0000-0001-8484-3475
Navarro-Compán, V.
Buño, A.
Heath, K. E.
Díaz-Almirón, M.
Balsa, A.
Tenorio, J. A.
Quer, J.
Aguado, P.
-
Funding
Funding for this research was provided by:
alexion pharmaceuticals
- License Information
-
More Information
Article History
Received: 30 July 2021
Accepted: 13 February 2022
First Online: 3 March 2022
Declarations
:
: The study adhered to the tenets of the Declaration of Helsinki and approval was obtained from La Paz University Hospital’s ethics committee. Each subject provided written informed consent prior to inclusion.
: Not applicable.
: Pilar Aguado and Carolina Tornero received grants related to this work (see funding section). Pilar Aguado has grants and personal fees from Abbvie, Alexion, Amgen, Faes, Gedeon-richter, GP-Pharm, Kyowa Kirin, Lilly, Rubió y Theramex outside the submitted work. V. Navarro-Compán reports grants and personal fees from Abbvie, Lilly, Pfizer, UCB, Novartis and Janssen outside the submitted work; Dr. Balsa reports grants, personal fees and other from Abbvie, Pfizer and Lilly, grants and personal fees from Novartis, UCB, Sanofi, Gilead, Galapagos and personal fees from BMS and Nordic outside the submitted work; C. Tornero, V. Navarro-Compán, A. Buño, K. Heath, M. Díaz-Almirón, A. Balsa, J. A. Tenorio, J. Quer and P. Aguado declare no other conflicts of interest.
